In the United States and Europe, gastroesophageal reflux (GER) is receiving attention as a potential cause of bronchial asthma. Few Japanese case reports have described this relationship. Therefore, we investigated the effect of omeprazole and cisapride on pulmonary function tests, blood gases and home peak expiratory flow rates (PEFR) in six Japanese outpatients with asthma and proven GER. After 8 weeks of treatment, reflux esophagitis had improved in all patients. However, the parameters of pulmonary function showed no change other than a significant posttreatment increase in home PEFR (4.4-27.7%) in three patients. These results suggest that anti-reflux (omeprazole and cisapride) treatment will produce small improvements in the PEFR in some Japanese asthmatics with GER.
INTRODUCTION
In the United States and Europe, gastroesophageal reflux (GER) has been demonstrated in approximately 40% of asthma patients.1,2 However, in Japan, few case reports have provided details regarding the relationship between these two {actors. 3 We have diagnosed GER in six of 21 perennial asthma patients (29%) via fiberoptic esophagoscopy. 4 We have also reported that many patients with asthma and concurrent GER have not been diagnosed. The body mass index (BMI) and gastric acid pH, which are closely related to the risk of GER,5 differ among races.6, 7 We therefore considered that investigation of the relationship between bronchoconstriction and GER in Japanese asthma patients was justified.
There have been some reports of pulmonary function data and peak expiratory flow rates (PEFR) obtained during histamine H2 receptor antagonist treatment in asthma patients with GER, but these results have been controversial. 8 The forced vital capacity (FVC), FEY1.0, V25/body height (V25/Ht) and arterial blood gas values (oxygen tension (PaO2), carbon dioxide tension (PaCO2), alveolararterial oxygen tension gradient (A-aDO2)) were also measured in asthma patients with evidence of reflux esophagitis. Pulmonary function was determined using a hot-wire flow meter (Autospiro AS-7; Minato Corp., Tokyo, Japan). Blood gas analysis was performed as follows: after patients had rested in a supine position for longer than 15min, blood samples were obtained from the brachial artery and were heparinized prior to injection into an automatic pH blood gas analyzer (Ciba Corning 278; Ciba-Corning Diagnostic Corp., Tokyo, Japan). The PaO2 and PaCO2 were measured in each sample. According to the method of Comroe,19 the ideal alveolar oxygen tension was calculated from the PaCO2. The A-aDO2 was calculated by subtracting PaO2 from the ideal alveolar oxygen tension.
Peak expiratory flow rates from the early morning and evening, which had been periodically recorded in asthma patients' diaries for 2 weeks prior to the study, were obtained. The patients were provided with a Wright minipeak flow meter (Clement Clark International Ltd, Harlow, UK). Three peak flow readings were taken at three time points and the highest value was entered on a diary card. Patients recorded their PEFR twice a day during omeprazole and cisapride treatment. Patients were also given an 8 week supply of omeprazole (20mg/day) and cisapride (7.5mg/day) tablets. Patients continued their conventional asthma therapy. After 8 weeks of treatment, the FVC, FEY1,0, V25/Ht, PaO2, and A-aDO2 were reassessed and repeat esophagoscopy was performed. 
RESULTS
All six patients who entered the study, completed the trial period. The subjects included four men and two women with a mean age of 53 years (range 33-61 years). All suffered perennial asthma attacks. Four patients had atopic disease and two had non-atopic disease. All patients were classified with moderate asthma (Table 1) . They were managed with oral theophylline (500-700 mg/day), an inhaled steroid (beclomethasone dipro- Pre-and post-treatment FVC, FEV1,0, V25/Ht and blood gas values did not differ significantly (Table 3) . Classification of reflux esophagitis according to the criteria of Savary and Miller18 showed that four patients had stage I disease and two had stage II disease. All cases of reflux esophagitis improved after treatment. Table 3 . Pulmonary function parameters before and after omeprazole and cisapride treatment in six asthma patients with reflux esophagitis times of the day did not differ significantly between preand post-treatment. However, three of six patients (patients SS, AY, MM) showed significantly increased PEFR at both times of the day after 8 weeks of treatment. The increases in early morning and evening PEFR in the three patients were calculated as (PEFR after 8 weeks of treatment) prior to the study) and were found to be 6.5, 27.7 and 24.3% and 4.4, 18.5 and 17.6%, respectively (Fig. 2a) . Two of six patients (patients YK and MK) showed significantly decreased PEFR and one (patient OH) showed no change in the PEFR at either time of the day (Fig. 2b) .
DISCUSSION
Suffering from reflux symptoms is an essential feature of that omeprazole and cisapride treatment effectively increases gastric acid pH and decreases GER without influencing theophylline concentration. The result of no significant difference between pre-and post-treatment PEFR was consistent with the results of the study of Ekstrom et al. 9 Our study subjects were stable asthmatics without symptoms during the preceding 6 weeks. The mean age of the patients in the study of Ekstrom et al. 9 was 59 years and their mean FEV, .a was 2.26 L. Thus, the degree of bronchoconstriction in the patients in the study of Ekstrom may have been similar to that in our subjects at the onset of the study. In contrast, different degrees of bronchoconstriction at the onset of the study (an FEY, o of 62% recorded by Goodall et al.8 compared with an FEY, o/FVC (2.33/3.40) of 69% in the present study) may have accounted for the different results between our study and that of Goodall et al.
In addition, gastric acid pH and degrees of obesity, which are both related to GER, differ among races.6,7 Therefore, we believe that differences among the subjects studied and the therapeutic agents used (H2 receptor antagonists vs omeprazole and cisapride) between these three studies may be related to the different results observed. In the present study the peak flow improvements were minor and probably of little clinical significance in our Japanese asthma patients with reflux esophagitis. Our study sample size was small, therefore, no definite conclusions can be drawn. In Japan, further study is needed to investigate the mechanism of GER-induced asthma.
